News | January 20, 2026
Syngene locks in Bristol Myers Squibb alliance through 2035
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Subscribe To Our Newsletter & Stay Updated
